EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile

Patient Name
Peterson, James

Date of Birth
22-DEC-1975

EpiSwitch PSE Risk Profile

Your Risk Level

Low Probability | **High Probability**

The **EpiSwitch Prostate Screening (PSE) Test** score indicates a **high likelihood of prostate cancer.** This result should be considered along with other clinical features for interpretation by a licensed medical professional.

A **HIGH PROBABILITY** result is not a prostate cancer diagnosis and requires follow-up diagnostic tests such as a biopsy ordered by your healthcare provider to confirm cancer.

Patient Information

Gender	Male
Medical Record #	c14456d0
Report #	PSE0254
Previous PSA test result (ng/mL)	3.0

Physician Release

Physician Name	Christopher Smith, MD, MS
Facility Name	XXX-XXX-XXX-XXX
Address	[Address line] [City], [State] [Zip]
Phone	811-555-4210
Account Ref	FL

Specimen Information

Report Date	28-FEB-2023
Receipt Date	28-FEB-2023
Collection Date	20-FEB-2023
Specimen Type	WB EDTA K3
Specimen ID	D000097422

EpiSwitch Prostate Screening Description

Intended Use: EpiSwitch Prostate Screening (PSE) Test is a blood-based screening test for prostate cancer which can be administered alongside or following a standard PSA test. The test evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

1. Pchejetski, D., et al. (2023). *Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection*. Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
2. Ishaker, H., et al. (2021). *Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups*. Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Screening (PSE) Test is a laboratory developed test (LDT). It has not been reviewed or cleared by the US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

This test was performed at Oxford BioDynamics, Inc., 7495 New Horizon Way, Frederick MD 21703 - CLIA # 21D2284653
For questions about the report, email PSE.TEST@myOBDX.com or call 1.888.236.8896

Medical Director

EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile

Patient Name
Peterson, James

Date of Birth
22-DEC-1975

EpiSwitch PSE Risk Profile

Your Risk Level

Low Probability | High Probability

The **EpiSwitch Prostate Screening (PSE) Test** score indicates a **low likelihood of prostate cancer.** This result should be considered along with other clinical features for interpretation by a licensed medical professional.

Patient Information

Gender	Male
Medical Record #	c14456d0
Report #	PSE0254
Previous PSA test result (ng/mL)	3.0

Physician Release

Physician Name	Christopher Smith, MD, MS
Facility Name	XXX-XXX-XXX-XXX
Address	[Address line] [City], [State] [Zip]
Phone	811-555-4210
Account Ref	FL

Specimen Information

Report Date	28-FEB-2023
Receipt Date	28-FEB-2023
Collection Date	20-FEB-2023
Specimen Type	WB EDTA K3
Specimen ID	D000097422

EpiSwitch Prostate Screening Description

Intended Use: EpiSwitch Prostate Screening (PSE) Test is a blood-based screening test for prostate cancer which can be administered alongside or following a standard PSA test. The test evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

1. Pchejetski, D., et al. (2023). *Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection*. Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
2. Ishaker, H., et al. (2021). *Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups*. Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Screening (PSE) Test is a laboratory developed test (LDT). It has not been reviewed or cleared by the US Food and Drug Administration. The laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

This test was performed at Oxford BioDynamics, Inc., 7495 New Horizon Way, Frederick MD 21703 - CLIA # 21D2284653
For questions about the report, email PSE.TEST@myOBDX.com or call 1.888.236.8896

Medical Director